Furthermore, recent evidence suggested that FGFR4 inhibitor lenvatinib enhances antitumor immune responses in gastric cancer by suppressing the FGF19–FGFR4 signaling axis149, thereby reducing tumor programmed cell death-ligand1 expression and modifying the tumor immune microenvironment. This evidence concerns the gene FGFR4 and gastric cancer.